DE69033192T2 - Aktive karbonate von polyalkylenoxyden zur modifizierung von polypeptiden - Google Patents

Aktive karbonate von polyalkylenoxyden zur modifizierung von polypeptiden

Info

Publication number
DE69033192T2
DE69033192T2 DE69033192T DE69033192T DE69033192T2 DE 69033192 T2 DE69033192 T2 DE 69033192T2 DE 69033192 T DE69033192 T DE 69033192T DE 69033192 T DE69033192 T DE 69033192T DE 69033192 T2 DE69033192 T2 DE 69033192T2
Authority
DE
Germany
Prior art keywords
oxydes
polyalkylene
polypeptides
modification
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69033192T
Other languages
English (en)
Other versions
DE69033192T3 (de
DE69033192D1 (de
Inventor
Shmuel Zalipsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enzon Pharmaceuticals Inc
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23335516&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69033192(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Application granted granted Critical
Publication of DE69033192D1 publication Critical patent/DE69033192D1/de
Publication of DE69033192T2 publication Critical patent/DE69033192T2/de
Publication of DE69033192T3 publication Critical patent/DE69033192T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Enzymes And Modification Thereof (AREA)
DE69033192T 1989-04-19 1990-04-19 Aktive karbonate von polyalkylenoxyden zur modifizierung von polypeptiden Expired - Lifetime DE69033192T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34092889A 1989-04-19 1989-04-19
US340928 1989-04-19
PCT/US1990/002133 WO1990013540A1 (en) 1989-04-19 1990-04-19 Active carbonates of polyalkylene oxides for modification of polypeptides

Publications (3)

Publication Number Publication Date
DE69033192D1 DE69033192D1 (de) 1999-08-05
DE69033192T2 true DE69033192T2 (de) 2000-03-09
DE69033192T3 DE69033192T3 (de) 2004-05-19

Family

ID=23335516

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69033192T Expired - Lifetime DE69033192T3 (de) 1989-04-19 1990-04-19 Aktive karbonate von polyalkylenoxyden zur modifizierung von polypeptiden
DE69034200T Expired - Lifetime DE69034200T2 (de) 1989-04-19 1990-04-19 Verfahren zum Herstellen von modifizierten Polypeptiden die eine Polypeptid und ein Polyalkylenoxid enthalten

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69034200T Expired - Lifetime DE69034200T2 (de) 1989-04-19 1990-04-19 Verfahren zum Herstellen von modifizierten Polypeptiden die eine Polypeptid und ein Polyalkylenoxid enthalten

Country Status (10)

Country Link
EP (2) EP0470128B2 (de)
JP (1) JP2875884B2 (de)
AT (2) ATE300519T1 (de)
AU (1) AU5526690A (de)
CA (1) CA2053317C (de)
DE (2) DE69033192T3 (de)
DK (2) DK0470128T4 (de)
ES (2) ES2247656T3 (de)
HU (1) HUT64022A (de)
WO (1) WO1990013540A1 (de)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5324844A (en) * 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
WO1992016555A1 (en) * 1991-03-18 1992-10-01 Enzon, Inc. Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
GB9116610D0 (en) * 1991-08-01 1991-09-18 Danbiosyst Uk Preparation of microparticles
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
CA2101361A1 (en) * 1992-08-27 1994-02-28 Robert A. Snow Low diol polyalkylene oxide biologically active proteinaceous substances
US5349001A (en) * 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5583114A (en) * 1994-07-27 1996-12-10 Minnesota Mining And Manufacturing Company Adhesive sealant composition
AU5893796A (en) * 1995-06-07 1996-12-30 Novo Nordisk A/S Modification of polypeptides
AU5893696A (en) * 1995-06-07 1996-12-30 Novo Nordisk A/S Modification of polypeptides
US6818018B1 (en) 1998-08-14 2004-11-16 Incept Llc In situ polymerizable hydrogels
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
ATE435033T1 (de) 2000-01-10 2009-07-15 Maxygen Holdings Ltd G-csf konjugate
RU2278123C2 (ru) 2000-02-11 2006-06-20 Максиджен Холдингз Лтд. Молекулы, подобные фактору vii или viia
ES2706000T3 (es) 2000-02-17 2019-03-27 Neomend Inc Procedimiento de producción de sistemas de administración utilizando composiciones poliméricas biodegradables preformadas
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
BR0207576A (pt) 2001-02-27 2004-04-27 Maxygen Aps Variante glicosilada de um polipeptìdeo de interferon beta precursor (ifnb), processos de aumentar a glicosilação in vivo de uma molécula de ifnb precursora, de produzir uma molécula de ifnb glicosilada, para preparar uma variante conjugada e de tratar um mamìfero com esclerose múltiplam composição farmacêutica, molécula de ifnb variante, sequência de nucleotìdeo, vetor de expressão, célula hospedeira de glicosilação conjugado, e, uso de um conjugado
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
DK1578771T3 (da) 2001-10-10 2013-06-10 Novo Nordisk As Remodellering og glycokonjugering af peptider
CN105131104B (zh) 2001-10-10 2018-11-16 诺和诺德公司 肽的重构和糖缀合
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
SI1499719T1 (sl) 2002-04-30 2011-03-31 Bayer Healthcare Llc Polipeptidne variante faktorja VII ali VIIa
UA86744C2 (en) 2002-06-21 2009-05-25 Ново Нордиск Хэлс Кеа Аг Pegylated factor vii glycoforms
WO2004061094A1 (en) 2002-12-30 2004-07-22 Gryphon Therapeutics, Inc. Water-soluble thioester and selenoester compounds and methods for making and using the same
JP2006523211A (ja) 2003-03-14 2006-10-12 ネオス テクノロジーズ インコーポレイテッド 分岐水溶性ポリマーとその複合物
EP2338333B1 (de) 2003-04-09 2017-09-06 ratiopharm GmbH Glycopegylierungsverfahren und durch die Verfahren hergestellte Proteine/Peptide
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
WO2004103275A2 (en) 2003-05-09 2004-12-02 Neose Technologies, Inc. Compositions and methods for the preparation of human growth hormone glycosylation mutants
GB0314472D0 (en) * 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
DE602004029173D1 (de) 2003-10-10 2010-10-28 Novo Nordisk As Il-21-derivate
EP2641611A3 (de) 2003-10-17 2013-12-18 Novo Nordisk A/S Kombinationstherapie
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US7842661B2 (en) 2003-11-24 2010-11-30 Novo Nordisk A/S Glycopegylated erythropoietin formulations
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
ES2560657T3 (es) 2004-01-08 2016-02-22 Ratiopharm Gmbh Glicosilación con unión en O de péptidos G-CSF
JP2007519422A (ja) 2004-02-02 2007-07-19 アンブレツクス・インコーポレイテツド 修飾されたヒト四螺旋バンドルポリペプチド及びそれらの使用
EP1748795A1 (de) * 2004-04-21 2007-02-07 Alza Corporation Unter milden thiolytischen bedingungen freisetzbares polymerkonjugat
WO2005123140A2 (en) 2004-06-08 2005-12-29 Alza Corporation Preparation of macromolecular conjugates by four-component condensation reaction
MXPA06014684A (es) 2004-06-18 2007-02-12 Ambrx Inc Novedosos polipeptidos de enlace antigeno y sus usos.
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
EP1799249A2 (de) 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegyliertes interferon alpha
SI2586456T1 (sl) 2004-10-29 2016-05-31 Ratiopharm Gmbh Preoblikovanje in glikopegliacija fibroblastnega rastnega faktorja (FGF)
ATE541934T1 (de) 2004-12-22 2012-02-15 Ambrx Inc Zusammensetzungen von aminoacyl-trna-synthetase und verwendungen davon
SG161210A1 (en) 2004-12-22 2010-05-27 Ambrx Inc Methods for expression and purification of recombinant human growth hormone
WO2006069246A2 (en) 2004-12-22 2006-06-29 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
BRPI0519430A2 (pt) 2004-12-22 2009-02-10 Ambrx Inc hormânio do crescimento humano modificado
AU2005322019B2 (en) 2004-12-22 2010-08-26 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid
EP1858543B1 (de) 2005-01-10 2013-11-27 BioGeneriX AG Glycopegylierten Granulocyten-Kolonie-stimulierender Faktor
US7365127B2 (en) * 2005-02-04 2008-04-29 Enzon Pharmaceuticals, Inc. Process for the preparation of polymer conjugates
US20100092505A1 (en) 2005-04-05 2010-04-15 Elisabetta Bianchi Method for Shielding Functional Sites or Epitopes on Proteins
WO2006121569A2 (en) 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP2975135A1 (de) 2005-05-25 2016-01-20 Novo Nordisk A/S Glykopegylierter Faktor IX
KR20080026135A (ko) 2005-06-03 2008-03-24 암브룩스, 인코포레이티드 개선된 인간 인터페론 분자 및 이의 용도
EP2360170A3 (de) 2005-06-17 2012-03-28 Novo Nordisk Health Care AG Selektive Reduktion und Derivatisierung von Proteinen die mindestens ein nicht-natives Cystein enthalten
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
EP2339014B1 (de) 2005-11-16 2015-05-27 Ambrx, Inc. Verfahren und Zusammensetzungen mit nichtnatürlichen Aminosäuren
EP1797901A1 (de) 2005-12-16 2007-06-20 Diatos Zelldurchlässige Peptidkonjugate zum Transfer von Nukleinsäuren in Zellen
AU2007227641B2 (en) 2006-03-13 2012-11-29 Liat Mintz Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite stimulation
US20090252720A1 (en) 2006-05-24 2009-10-08 Novo Nordisk Health Care Ag Prolonged FIX Analogues and Derivatives
CN101516388B (zh) 2006-07-21 2012-10-31 诺和诺德公司 通过o-联糖基化序列的肽的糖基化
EP2069396B1 (de) 2006-09-08 2015-10-21 Ambrx, Inc. Modifiziertes polypeptid oder fc-gerüste aus humanem plasma und ihre verwendung
NZ574721A (en) 2006-09-08 2012-02-24 Ambrx Inc Hybrid suppressor trna for vertebrate cells
US8420792B2 (en) 2006-09-08 2013-04-16 Ambrx, Inc. Suppressor tRNA transcription in vertebrate cells
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
EP2054521A4 (de) 2006-10-03 2012-12-19 Novo Nordisk As Verfahren zur reinigung von polypeptid-konjugate
CN101600448B (zh) 2006-10-04 2015-11-25 诺和诺德公司 甘油连接的peg化的糖和糖肽
BRPI0809583B1 (pt) 2007-03-30 2022-02-22 Ambrx, Inc Polipeptídeo fgf-21 modificado, composição compreendendo o mesmo, método para produzir o referido polipetídeo fgf-21 e célula compreendendo um polinucleotídeo
ES2406267T3 (es) 2007-04-03 2013-06-06 Biogenerix Ag Métodos de tratamiento usando G-CSF glicopegilado
CA2685596A1 (en) 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
NZ603812A (en) 2007-11-20 2014-06-27 Ambrx Inc Modified insulin polypeptides and their uses
SG188143A1 (en) 2008-02-08 2013-03-28 Ambrx Inc Modified leptin polypeptides and their uses
PL2257311T3 (pl) 2008-02-27 2014-09-30 Novo Nordisk As Koniugaty cząsteczek czynnika VIII
EP2300514B1 (de) * 2008-07-14 2016-03-23 Biocon Limited Verfahren zur synthese einer weitgehend monodispersen mischung von oligomeren
NZ591235A (en) 2008-07-23 2012-07-27 Ambrx Inc Modified bovine g-csf polypeptides comprising non natural amino acid and their uses treating infections such as mastitis
TR201802361T4 (tr) 2008-09-26 2018-03-21 Ambrx Inc Doğal olmayan amino asit replikasyonuna bağımlı mikroorganizmalar ve aşılar.
PL2342223T3 (pl) 2008-09-26 2017-09-29 Ambrx, Inc. Zmodyfikowane polipeptydy zwierzęcej erytropoetyny i ich zastosowania
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
NZ597022A (en) 2009-06-09 2014-05-30 Prolong Pharmaceuticals Llc Hemoglobin compositions
NZ600361A (en) 2009-12-21 2014-06-27 Ambrx Inc Modified bovine somatotropin polypeptides and their uses
CN104017063A (zh) 2009-12-21 2014-09-03 Ambrx公司 经过修饰的猪促生长素多肽和其用途
JP6148013B2 (ja) 2010-03-05 2017-06-14 リグショスピタレト 補体活性化のキメラ抑制分子
EP2569331A1 (de) 2010-05-10 2013-03-20 Perseid Therapeutics LLC Polypeptid-inhibitoren von vla4
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
MY162837A (en) 2010-08-17 2017-07-31 Ambrx Inc Modified relaxin polypeptides and their uses
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
CN103429256B (zh) 2011-03-02 2022-09-13 诺和诺德保健股份有限公司 凝血因子向活化的血小板上的tlt-1的靶向
JP6166258B2 (ja) 2011-06-15 2017-07-19 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ブレビバクテリウム・オーランチアカム（Ｂｒｅｖｉｂａｃｔｅｒｉｕｍａｕｒａｎｔｉａｃｕｍ）から単離されたポリペプチド及び癌の治療を目的とするその使用
CN103930440A (zh) 2011-07-01 2014-07-16 拜耳知识产权有限责任公司 松弛素融合多肽及其用途
CN103747807B (zh) 2011-07-05 2016-12-07 比奥阿赛斯技术有限公司 P97‑抗体缀合物和使用方法
AU2013255880B2 (en) 2012-05-01 2017-07-20 Novo Nordisk A/S Pharmaceutical composition
EP2859017B1 (de) 2012-06-08 2019-02-20 Sutro Biopharma, Inc. Antikörper mit nichtnatürlichen stellenspezifischen aminosäureresten, verfahren zu deren herstellung und verfahren zu deren verwendung
DK2863955T3 (en) 2012-06-26 2017-01-23 Sutro Biopharma Inc MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
EP2880156B1 (de) 2012-07-31 2017-08-23 biOasis Technologies Inc Dephosphorylierte proteine lysosomaler speicherkrankheiten und verwendung davon
EP3584255B1 (de) 2012-08-31 2022-02-16 Sutro Biopharma, Inc. Modifizierte aminosäuren mit einer azidogruppe
CA2890190A1 (en) 2012-11-12 2014-05-15 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
JP2016505528A (ja) 2012-11-16 2016-02-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア タンパク質の化学修飾のためのピクテ−スペングラーライゲーション
WO2014160438A1 (en) 2013-03-13 2014-10-02 Bioasis Technologies Inc. Fragments of p97 and uses thereof
US9896513B2 (en) 2013-03-15 2018-02-20 Novo Nordisk A/S Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor
US9764039B2 (en) 2013-07-10 2017-09-19 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
EP3038657A2 (de) 2013-08-28 2016-07-06 Bioasis Technologies Inc. Cns-gerichtete konjugate mit modifizierten fc-regionen und verfahren zur verwendung davon
JP6745218B2 (ja) 2013-11-27 2020-08-26 レッドウッド バイオサイエンス， インコーポレイテッド ヒドラジニル−ピロロ化合物及び複合体を生成するための方法
UY36370A (es) 2014-10-24 2016-04-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Polipéptidos fgf-21 modificados y sus usos
WO2017029391A1 (en) 2015-08-20 2017-02-23 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating cancer
EP3463308B1 (de) * 2016-06-01 2021-12-01 Servier IP UK Limited Formulierungen von polyalkylen-oxid-asparaginase und verfahren zur herstellung und verwendung davon
CN109891237B (zh) 2016-10-24 2022-08-23 诺和诺德股份有限公司 胰岛素制剂的生物测定法
ES2963839T3 (es) 2017-02-08 2024-04-02 Bristol Myers Squibb Co Polipéptidos de relaxina modificados que comprenden un potenciador farmacocinético y usos de los mismos
WO2019038420A1 (en) 2017-08-25 2019-02-28 INSERM (Institut National de la Santé et de la Recherche Médicale) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OSTEOCLAST DISEASES
US11492493B2 (en) 2017-12-26 2022-11-08 Becton, Dickinson And Company Deep ultraviolet-excitable water-solvated polymeric dyes
JP2021519841A (ja) 2018-03-30 2021-08-12 ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ ペンダントクロモフォアを有する水溶性ポリマー色素
CA3107332A1 (en) 2018-07-22 2020-01-30 Bioasis Technologies Inc. Treatment of lymphatic metastases
HRP20240016T1 (hr) 2018-09-11 2024-03-29 Ambrx, Inc. Konjugati polipeptida interleukina-2 i njihove uporabe
WO2020089743A1 (en) 2018-11-02 2020-05-07 Cadila Healthcare Limited Pharmaceutical composition of pegylated l-asparaginase
WO2021048171A1 (en) 2019-09-10 2021-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to improve phagocytosis
WO2021183832A1 (en) 2020-03-11 2021-09-16 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
US20210355468A1 (en) 2020-05-18 2021-11-18 Bioasis Technologies, Inc. Compositions and methods for treating lewy body dementia
US20210393787A1 (en) 2020-06-17 2021-12-23 Bioasis Technologies, Inc. Compositions and methods for treating frontotemporal dementia
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
US20220211900A1 (en) 2020-12-28 2022-07-07 Davol Inc. Reactive dry powdered hemostatic materials comprising a protein and a multifunctionalized modified polyethylene glycol based crosslinking agent
WO2022152698A1 (en) 2021-01-12 2022-07-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of npdk-d to evaluate cancer prognosis
WO2022200469A1 (en) 2021-03-24 2022-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) A dominant negative protein of rad51 for treating cancer
EP4155349A1 (de) 2021-09-24 2023-03-29 Becton, Dickinson and Company Wasserlösliche gelbe grünabsorbierende farbstoffe
CN114965761B (zh) * 2022-05-17 2024-07-02 深圳赛保尔生物药业有限公司 聚乙二醇化蛋白药物中n-羟基琥珀酰亚胺的检测方法
WO2024007016A2 (en) 2022-07-01 2024-01-04 Beckman Coulter, Inc. Novel fluorescent dyes and polymers from dihydrophenanthrene derivatives
WO2024044327A1 (en) 2022-08-26 2024-02-29 Beckman Coulter, Inc. Dhnt monomers and polymer dyes with modified photophysical properties

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2631656C2 (de) * 1976-07-14 1983-02-10 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung eines Hydroxysuccinimidoester-Derivats zur Bindung von biologisch aktiven Proteinen aneinander und/oder an flüssige oder feste Trägerstoffe
CS204190B1 (en) † 1978-02-22 1981-03-31 Jaroslav Drobnik Activation method for hydrxyl groups containing insoluble carriers
YU144584A (en) † 1983-08-25 1987-06-30 Akad Wissenschaften Ddr Process for making n-(chlorocarbonyloxi)-s-norbornen-2,3-dicarboximide
DD219490A1 (de) † 1983-10-28 1985-03-06 Akad Wissenschaften Ddr Verfahren zur herstellung aktivierter traeger
JPS60156395A (ja) * 1984-01-17 1985-08-16 Mihama Hisaharu 修飾リパーゼ
DE3413904A1 (de) * 1984-04-13 1985-10-24 Hoechst Ag, 6230 Frankfurt Polymerisate auf basis von polyvinylencarbonat und/oder polyhydroxymethylen, verfahren zu ihrer herstellung und ihre anwendung
FR2574075B1 (fr) * 1984-12-04 1987-09-18 Poudres & Explosifs Ste Nale Procede de synthese d'esters actifs d'acides carboxyliques, nouveaux carbonates alpha-halogenes utiles pour cette synthese et leur mode d'obtention
JPH0757760B2 (ja) * 1987-06-05 1995-06-21 宇部興産株式会社 生体由来物質の固定化方法
DD260701A1 (de) † 1987-06-30 1988-10-05 Akad Wissenschaften Ddr Verfahren zur umesterung von aktiven unsymmetrischen kohlensaeurediester-gruppen an hydroxylgruppenhaltigen polymeren
DD261791A1 (de) † 1987-06-30 1988-11-09 Akad Wissenschaften Ddr Verfahren zur herstellung von carbonaten hydroxylgruppenhaltiger polymere
IE64284B1 (en) † 1987-08-03 1995-07-26 Ddi Pharmaceuticals Conjugates of superoxide dismutase
US4847325A (en) † 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1

Also Published As

Publication number Publication date
ES2247656T3 (es) 2006-03-01
DK0893439T3 (da) 2005-09-05
JPH04504872A (ja) 1992-08-27
CA2053317A1 (en) 1990-10-20
AU5526690A (en) 1990-11-29
EP0893439A1 (de) 1999-01-27
DK0470128T4 (da) 2003-12-01
ATE300519T1 (de) 2005-08-15
EP0470128B1 (de) 1999-06-30
EP0470128B2 (de) 2003-08-13
DE69033192T3 (de) 2004-05-19
EP0893439B1 (de) 2005-07-27
CA2053317C (en) 1996-03-12
DE69034200T2 (de) 2006-05-24
HUT64022A (en) 1993-11-29
ES2136595T5 (es) 2004-04-01
EP0470128A4 (en) 1992-09-16
ES2136595T3 (es) 1999-12-01
DE69034200D1 (de) 2005-09-01
JP2875884B2 (ja) 1999-03-31
HU903628D0 (en) 1991-12-30
DE69033192D1 (de) 1999-08-05
ATE181732T1 (de) 1999-07-15
DK0470128T3 (da) 2000-01-10
WO1990013540A1 (en) 1990-11-15
EP0470128A1 (de) 1992-02-12

Similar Documents

Publication Publication Date Title
DE69033192D1 (de) Aktive karbonate von polyalkylenoxyden zur modifizierung von polypeptiden
ATE424431T2 (de) Verfahren zur herstellung von 1- benzotriazolcarbonatestern von wasserlöslichen polymeren
ATE142644T1 (de) Biosynthetische osteogene proteine und sie enthaltende osteogene vorrichtungen
ES2124685T3 (es) Variantes del inhibidor de la tripsina pancreatica bovina, su produccion y uso.
DE69521901T2 (de) Spritzgegossene darreichungsform
PT94732A (pt) Processo para a preparacao de composicoes contendo um polipeptido da proteina morfogenetica do tecido osseo
DK491487A (da) Dna-sekvens til ekspressionering af biologisk aktivt faktor xiii og anvendelse af samme
MC1884A1 (fr) Variants de l'hirudine,leur utilisation et leur preparation
FI905825A0 (fi) Amfifiliska peptider och deras anvaendning.
ATE346096T1 (de) G-csf tpo fusionsproteine
ES2144392T3 (es) Vectores de expresion para la sintesis de proteinas en la levadura de escision schizosaccharomyces pombe.
DK0732339T3 (da) Peptider fra HIV-gag-proteinet, fremstilling og anvendelse deraf
ATE286746T1 (de) Proteinhaltige hydrogele
DE3680524D1 (de) Verfahren zur stabilisierung von proteinen.
ES2129022T3 (es) Proteina condromodulina-i.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: ENZON, INC., PISCATAWAY, N.J., US

8366 Restricted maintained after opposition proceedings